The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
TD Cowen has increased its price target for DaVita to $201 from $144 while maintaining a Hold rating on the stock. This adjustment follows the company's robust financial performance in the first quarter of 2026, during which DaVita reported a 6% growth in revenue. According to reports, the shares are currently trading near their 52-week highs, bolstered by strong fundamental results despite recent instances of insider selling.
Sign in to access this content
Sign InThe price target hike of nearly 40% reflects confidence in DaVita's strategic positioning within the US healthcare sector, which continues to benefit from an aging population and rising demand for dialysis services. Compared to industry peers, DaVita has shown significant operational resilience; for context, major healthcare providers have maintained stable margins despite cost pressures, per market data. This optimism is further supported by the company's projected growth trajectory for fiscal year 2026.
Investors should watch current price levels as the stock approaches its new target, keeping broader market volatility in mind. Looking at the economic calendar, US employment data, such as the unemployment rate which held at 4.3% (as of May 8, 2026), may influence market sentiment toward healthcare and growth stocks. Additionally, upcoming speeches from Fed officials will be critical for assessing the interest rate environment and its impact on corporate financing costs.